World Evidence, Pricing and Access Congress Europe 2026

World Evidence, Pricing and Access Congress Europe (March 3–4, 2026) at RAI Amsterdam covers market access, pricing, reimbursement, rare diseases, HTA, and health economics. The congress features 250+ speakers, 120+ exhibitors, and 1500+ attendees, with 10 tracks focusing on evidence generation and pricing strategies. Organized by Terrapinn Holdings Ltd., the event enables networking, one-to-one meetings, and collaboration among pharma, biotech, and payer stakeholders to drive market access success.

Range of Exhibition

• Market Access:
  Market access strategy, payer engagement, access planning, reimbursement pathways.
• Evidence:
  Real-world evidence, clinical evidence, data generation, outcomes research.
• Rare Diseases:
  Rare disease access, orphan drug pricing, specialty care reimbursement.
• Pre-launch Success:
  Pre-launch planning, launch readiness, early access programs.
• Pricing:
  Pricing strategy, value-based pricing, price negotiation.
• HTA/Payer:
  Health technology assessment, payer evaluation, reimbursement decision support.
• Digital Transformation & Real World Data:
  Digital tools, RWD platforms, data analytics, digital evidence generation.
• Reimbursement:
  Reimbursement policies, funding pathways, payer contracts.
• Risk Management:
  Risk-sharing agreements, patient access schemes, compliance and risk frameworks.
• Health Economics & Outcomes Research:
  Cost-effectiveness analysis, HEOR modeling, budget impact studies.

Target Audience

Pharma executives, biotech leaders, market access professionals, pricing managers, HTA experts, payers, healthcare policymakers, real-world evidence researchers, reimbursement specialists, rare disease stakeholders.